Eli Lilly’s TuneLab, the pharmaceutical giant’s first-of-its-kind AI initiative, has reached a milestone of 100 members and is adding AI models from Chai, according to a report from Endpoints News.
TuneLab represents a novel approach for the drugmaker, applying artificial intelligence to accelerate drug discovery and development. The initiative has grown rapidly, attracting 100 participants within its ecosystem as it expands the scope of AI models available to researchers.
The addition of Chai’s AI models signals Eli Lilly’s commitment to integrating external AI capabilities alongside its internal efforts. Chai is known for developing large language models and conversational AI technologies, and the collaboration could open new avenues for applying AI in pharmaceutical research.
The leader behind TuneLab, speaking about the initiative’s launch, said they had no idea what to expect when it started. The program has since become a test case for how major pharmaceutical companies can leverage AI to improve drug discovery pipelines.
The milestone comes amid a broader push across the pharmaceutical industry to adopt AI-driven approaches. Major drugmakers are increasingly investing in AI capabilities to reduce the time and cost of bringing new therapies to market, from target identification through clinical trial design.
Source: Endpoints News
